This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-13. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
== Specialized hardware for MD simulations == Anton – A specialized, massively parallel supercomputer designed to execute MD simulations MDGRAPE – A special purpose system built for molecular dynamics simulations, especially protein structure prediction
Produce a book and a film about Omar ibn Said Provide public access to "programs that enhance knowledge about faiths practiced in the regions, including Indigenous African religious traditions, Judaism, Christianity, Islam, and their influence on daily life." On May 8, 2025, two days after Hayden had given testimony to the Senate Committee on Appropriations and the Committee on House Administration, via email and without any explanation, she was abruptly fired by President Trump. Publishers Weekly characterized Hayden's termination as the "latest blow to professional research and the literary and arts community." No replacement of Hayden has been nominated. Principal Deputy Librarian Robert Newlen, who would have served as interim librarian was fired and Trump named Deputy Attorney General Todd Blanche as acting librarian of Congress and later fired the deputy librarian and copyright office director (Perlmutter and Newlen), appointing senior DOJ officials Brian Nieves and Paul Perkins as respectively, for the interim. This has been interpreted as an attack on the separation of powers. Perlmutter has sued to dispute the legality of the dismissal, as the register is appointed by, and responsible to, the librarian of Congress.
The supply of PUFAs for ferroptosis also depends on glutaminolysis — the uptake of glutamine via membrane transporters SLC38A1 and SLC1A5, its conversion to α-ketoglutarate, and subsequent mitochondrial catabolism to generate acetyl-CoA for fatty acid synthesis. This process is regulated by AMP-activated protein kinase (AMPK), which plays a dual role in ferroptosis through phosphorylation of either Beclin-1 or acetyl-CoA carboxylase. Under stress conditions, lipid droplets can also release free fatty acids, further amplifying lipid peroxidation. Ferroptosis has been shown to involve distinct cellular organelles, which includes peroxisomes, mitochondria, the endoplasmic reticulum (ER) and lysosomes. It has been a debate in the scientific community as to where ferroptosis is initiated in the cell, and now research points to the lysosome, where the chemical environment (iron, pH an hydrogen peroxide) are favorable. Oxidation of phospholipids can occur when free radicals abstract electrons from a lipid molecule (typically affecting polyunsaturated fatty acids), thereby promoting their oxidation. The primary cellular mechanism of protection against ferroptosis is mediated by the selenoprotein GPX4, a glutathione-dependent hydroperoxidase that converts lipid hydroperoxides into non-toxic lipid alcohols. The abundant lipid soluble vitamin α-tocopherol complements GPX4 by acting as a radical-trapping antioxidant for lipid peroxyl radicals, the chief membrane damaging species in ferroptosis that cannot be reduced by GPX4.
=== Legal status === Tiratricol was once an approved medication in Brazil, but its marketing authorization was suspended in 2003. Tiratricol is available in France for therapy of thyroid hormone resistance and adjuvant therapy of thyroid cancer. In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Emcitate, intended for the treatment of MCT8 deficiency (Allan-Herndon-Dudley syndrome). The applicant for this medicinal product is Rare Thyroid Therapeutics International AB. Emcitate is a hybrid medicine of Téatrois, which has been authorized in France. Emcitate contains the same active substance as Téatrois but has a different indication. Tiratricol was authorized for medical use in the European Union in February 2025. Tiratricol was approved for medical use in the United States in September 2026. The US Food and Drug Administration (FDA) granted the application for tiratricol orphan drug, rare pediatric disease, fast track, breakthrough therapy, and priority review designations. The FDA granted the approval of Emcitate to Egetis Therapeutics US.
Sources: en.wikipedia.org
=== Services === As of 2014, the Cherokee Seed Project of the Natural Resources Department offers "two breeds of corn, two kinds of beans (including Trail of Tears beans), two gourds and medicinal tobacco" to Cherokee Nation members. Eleven satellite communities have been organized by the tribe in areas of high Cherokee Nation populations. These communities are composed of a majority of enrolled Cherokee Nation citizens. These communities are a way for enrolled Cherokee citizens to connect with Cherokee heritage and culture, and to be more politically engaged. These communities are located in Arizona, California, Colorado, New Mexico, Texas, Florida, and central Oklahoma.
== Employee relations and opportunities == In February 2019, employees of three Ohio locations resigned en masse due to management changes, as well as what they alleged was a 50% reduction of the employee hourly pay rate, a claim denied by Sonic. In 2020, Sonic added a tipping feature via the online ordering app. In 2021, Sonic added an option to tip at the stalls.
=== Pain === Preclinical data support the notion that Substance P is an important element in pain perception. The sensory function of Substance P is thought to be related to the transmission of pain information into the central nervous system. Substance P coexists with the excitatory neurotransmitter glutamate in primary afferents that respond to painful stimulation. Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle, and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury. Unfortunately, the reasons why NK1 receptor antagonists have failed as efficacious analgesics in well-conducted clinical proof of concept studies have not yet been persuasively elucidated.
Sources: en.wikipedia.org
=== Over-reporting by China === China overwhelmingly dominates the world in reported aquaculture output, reporting a total output which is double that of the rest of the world put together. However, there are some historical issues with the accuracy of China's returns. In 2001, scientists Reg Watson and Daniel Pauly expressed concerns that China was over reporting its catch from wild fisheries in the 1990s. They said that made it appear that the global catch since 1988 was increasing annually by 300,000 tonnes, whereas it was really shrinking annually by 350,000 tonnes. Watson and Pauly suggested this may have been related to Chinese policies where state entities that monitored the economy were also tasked with increasing output. Also, until more recently, the promotion of Chinese officials was based on production increases from their own areas. China disputed this claim. The official Xinhua News Agency quoted Yang Jian, director general of the Agriculture Ministry's Bureau of Fisheries, as saying that China's figures were "basically correct". However, the FAO accepted there were issues with the reliability of China's statistical returns, and for a period treated data from China, including the aquaculture data, apart from the rest of the world.
Napoleon took the reserve of the Army of the North, and reunited his forces with those of Ney to pursue Wellington's army, after he ordered Marshal Grouchy to take the right wing of the Army of the North and stop the Prussians regrouping. In the first of a series of miscalculations, both Grouchy and Napoleon failed to realise that the Prussian forces were already reorganised and were assembling at the city of Wavre. The French army did nothing to stop a rather leisurely retreat that took place throughout the night and into the early morning by the Prussians. As the 4th, 1st, and 2nd Prussian Corps marched through the town towards Waterloo, the 3rd Prussian Corps took up blocking positions across the river, and although Grouchy engaged and defeated the Prussian rearguard under the command of Lt-Gen von Thielmann in the Battle of Wavre (18–19 June) it was 12 hours too late. In the end, 17,000 Prussians had kept 33,000 badly needed French reinforcements off the field. Napoleon delayed the start of fighting at the Battle of Waterloo on the morning of 18 June for several hours while he waited for the ground to dry after the previous night's rain. By late afternoon, the French army had not succeeded in driving Wellington's forces from the escarpment on which they stood. When the Prussians arrived and attacked the French right flank in ever-increasing numbers, Napoleon's strategy of keeping the coalition armies divided had failed and a combined coalition general advance drove his army from the field in confusion.
== Neuromodulator == GSSG, along with glutathione and S-nitrosoglutathione (GSNO), have been found to bind to the glutamate recognition site of the NMDA and AMPA receptors (via their γ-glutamyl moieties), and may be endogenous neuromodulators. At millimolar concentrations, they may also modulate the redox state of the NMDA receptor complex.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.